Evidence map›Paper›PMID 32042611›Full record

ArticlePublic health action2019

Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents.

E Mohr-Holland, I Apolisi, A Reuter, V de Azevedo, J Hill, S Matthee, J A Seddon, P Isaakidis, J Furin, L Trivino-Duran

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health action, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Pediatric delamanid treatment for children with rifampicin-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

E Mohr-HollandMédecins Sans Frontières (MSF), Khayelitsha and Cape Town, South Africa.
I ApolisiMédecins Sans Frontières (MSF), Khayelitsha and Cape Town, South Africa.
A ReuterMédecins Sans Frontières (MSF), Khayelitsha and Cape Town, South Africa.
V de AzevedoCity Health Department, Cape Town, South Africa.
J HillTechnical Division, KNCV Tuberculosefonds, The Hague, Netherlands.
S MattheeProvincial Government of the Western Cape Health Department, Cape Town, South Africa.
J A SeddonDesmond Tutu TB Centre, Department of Paediatric and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
P IsaakidisSouthern Africa Medical Unit, MSF, Cape Town, South Africa.
J FurinHarvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA.
L Trivino-DuranMédecins Sans Frontières (MSF), Khayelitsha and Cape Town, South Africa.
Médecins Sans Frontières · ZACity of Cape Town · ZADesmond Tutu HIV Foundation · ZAHarvard Global Health Institute · USKoninklijke Nederlandse Chemische Vereniging · NLWestern Cape Department of Health · ZA

Funding

Medical Research Council MR/R007942/1
6 · The paper itself

Abstract

Little is known about the barriers to post-exposure management of rifampicin-resistant tuberculosis (RR-TB) in older children and adolescents. We report on implementation lessons from a pilot programme targeting household-exposed individuals aged 6-18 years in Khayelitsha, South Africa. Barriers included misperceptions regarding risk of exposure, multiple research and implementation stakeholders, additional workload for an overburdened healthcare system, logistical issues faced by families, and insufficient human and financial resources. Solutions to these barriers are possible, but creativity and persistence are required. Our experience can guide others looking to roll-out care for children and adolescents exposed to RR-TB.

Indexed as

Khayelitshapost-exposure managementRR-TBSouth Africavulnerable populations

Identifiers

PMID32042611
PMCPMC6945730
OpenAlexW2999906493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.